{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:20:09Z","timestamp":1768569609050,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00393-022-01165-w","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T16:02:30Z","timestamp":1644508950000},"page":"88-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a\u00a0network meta-analysis","Relative Remissionsraten von Januskinaseinhibitoren im Vergleich zu Adalimumab bei Patienten mit aktiver rheumatoider Arthritis: eine Netzwerk-Metaanalyse"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-1909","authenticated-orcid":false,"given":"Young Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwan Gyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"issue":"2","key":"1165_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4078\/jrd.2021.28.2.60","volume":"28","author":"H Kim","year":"2021","unstructured":"Kim\u00a0H, Sung\u00a0Y\u2011K (2021) Epidemiology of rheumatoid arthritis in Korea. J\u00a0Rheum Dis 28(2):60\u201367","journal-title":"J Rheum Dis"},{"issue":"4","key":"1165_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen\u00a0JS, Aletaha\u00a0D, Bijlsma\u00a0JW, Breedveld\u00a0FC, Boumpas\u00a0D, Burmester\u00a0G et\u00a0al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631\u2013637","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1165_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson\u00a0J, Caplan\u00a0L, Yazdany\u00a0J, Robbins\u00a0ML, Neogi\u00a0T, Michaud\u00a0K et\u00a0al (2012) Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice. Arthritis Care Res 64(5):640\u2013647","journal-title":"Arthritis Care Res"},{"issue":"6","key":"1165_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells\u00a0G, Becker\u00a0J, Teng\u00a0J, Dougados\u00a0M, Schiff\u00a0M, Smolen\u00a0J et al (2009) Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C\u2011reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68(6):954\u2013960","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1165_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4078\/jrd.2016.23.4.241","volume":"23","author":"S Gwan Gyu","year":"2016","unstructured":"Gwan Gyu\u00a0S, Young Ho\u00a0L (2016) Comparison of disease activity score 28 using C\u2011reactive protein and disease activity score 28 using erythrocyte sedimentation rate in assessing activity and treatment response in rheumatoid arthritis: a meta-analysisu. J\u00a0Rheum Dis 23(4):241\u2013249","journal-title":"J Rheum Dis"},{"issue":"3","key":"1165_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/art.39945","volume":"69","author":"ME Mack","year":"2017","unstructured":"Mack\u00a0ME, Hsia\u00a0E, Aletaha\u00a0D (2017) Comparative assessment of the different American college of rheumatology\/European league against rheumatism remission definitions for rheumatoid arthritis for their use as clinical trial end points. Arthritis Rheumatol 69(3):518\u2013528","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"1165_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/acr.24042","volume":"71","author":"BR England","year":"2019","unstructured":"England\u00a0BR, Tiong\u00a0BK, Bergman\u00a0MJ, Curtis\u00a0JR, Kazi\u00a0S, Mikuls\u00a0TR et\u00a0al (2019) 2019 update of the American college of rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res 71(12):1540\u20131555","journal-title":"Arthritis Care Res"},{"issue":"4","key":"1165_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1303006","volume":"369","author":"JR O\u2019Dell","year":"2013","unstructured":"O\u2019Dell\u00a0JR, Mikuls\u00a0TR, Taylor\u00a0TH, Ahluwalia\u00a0V, Brophy\u00a0M, Warren\u00a0SR et\u00a0al (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N\u00a0Engl J Med 369(4):307\u2013318","journal-title":"N Engl J Med"},{"issue":"5","key":"1165_CR9","first-page":"689","volume":"56","author":"E Choy","year":"2017","unstructured":"Choy\u00a0E, Aletaha\u00a0D, Behrens\u00a0F, Finckh\u00a0A, Gomez-Reino\u00a0J, Gottenberg\u00a0J\u2011E et al (2017) Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology 56(5):689\u2013697","journal-title":"Rheumatology"},{"issue":"1","key":"1165_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi\u00a0K, Laurence\u00a0A, O\u2019Shea\u00a0JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273\u2013287","journal-title":"Immunol Rev"},{"issue":"5646","key":"1165_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.1087061","volume":"302","author":"PS Changelian","year":"2003","unstructured":"Changelian\u00a0PS, Flanagan\u00a0ME, Ball\u00a0DJ, Kent\u00a0CR, Magnuson\u00a0KS, Martin\u00a0WH et\u00a0al (2003) Prevention of organ allograft rejection by a\u00a0specific Janus kinase 3 inhibitor. Science 302(5646):875\u2013878","journal-title":"Science"},{"issue":"12","key":"1165_CR12","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"JG Shi","year":"2014","unstructured":"Shi\u00a0JG, Chen\u00a0X, Lee\u00a0F, Emm\u00a0T, Scherle\u00a0PA, Lo\u00a0Y et\u00a0al (2014) The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J\u00a0Clin Pharmacol 54(12):1354\u20131361","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1165_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi\u00a0K, Laurence\u00a0A, O\u2019Shea\u00a0JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273\u2013287","journal-title":"Immunol Rev"},{"issue":"2","key":"1165_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00001721-199404000-00003","volume":"5","author":"T Nakase","year":"1994","unstructured":"Nakase\u00a0T, Wada\u00a0H, Minamikawa\u00a0K, Wakita\u00a0Y, Shimura\u00a0M, Hiyoyama\u00a0K et al (1994) Increased activated protein C\u2011protein C inhibitor complex level in patients positive for lupus anticoagulant. Blood Coagul Fibrinolysis 5(2):173\u2013177","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"10093","key":"1165_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann\u00a0R, Mysler\u00a0E, Hall\u00a0S, Kivitz\u00a0AJ, Moots\u00a0RJ, Luo\u00a0Z et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468","journal-title":"Lancet"},{"issue":"7","key":"1165_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor\u00a0PC, Keystone\u00a0EC, van der Heijde\u00a0D, Weinblatt\u00a0ME, Del Carmen Morales\u00a0L, Reyes Gonzaga\u00a0J et\u00a0al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N\u00a0Engl J Med 376(7):652\u2013662","journal-title":"N Engl J Med"},{"key":"1165_CR17","volume-title":"A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate","year":"2018","unstructured":"Fleischmann\u00a0R, Pangan\u00a0AL, Mysler\u00a0E, Bessette\u00a0L, Peterfy\u00a0C, Durez\u00a0P et al (eds) (2018) A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. Wiley, Hoboken"},{"key":"1165_CR18","volume-title":"Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results","author":"B Combe","year":"2019","unstructured":"Combe\u00a0B, Kivitz\u00a0A, Tanaka\u00a0Y, van der Heijde\u00a0D, Matzkies\u00a0F, Bartok\u00a0B et\u00a0al (2019) Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. BMJ Publishing Group Ltd, (LB0001)"},{"issue":"3","key":"1165_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4078\/jrd.2018.25.3.169","volume":"25","author":"YH Lee","year":"2018","unstructured":"Lee\u00a0YH (2018) Association between the neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and rheumatoid arthritis and their correlations with the disease activity: a meta-analysis. J\u00a0Rheum Dis 25(3):169\u2013178","journal-title":"J Rheum Dis"},{"issue":"3","key":"1165_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3343\/alm.2015.35.3.283","volume":"35","author":"YH Lee","year":"2015","unstructured":"Lee\u00a0YH (2015) Meta-analysis of genetic association studies. Ann Lab Med 35(3):283\u2013287","journal-title":"Ann Lab Med"},{"issue":"4","key":"1165_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4078\/jrd.2017.24.4.211","volume":"24","author":"YH Lee","year":"2017","unstructured":"Lee\u00a0YH, Song\u00a0GG (2017) Comparative efficacy and safety of secukinumab and adalimumab in patients with active ankylosing spondylitis: a\u00a0Bayesian network meta-analysis of randomized controlled trials. J\u00a0Rheum Dis 24(4):211\u2013219","journal-title":"J Rheum Dis"},{"issue":"5","key":"1165_CR22","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.1780350502","volume":"35","author":"MC Hochberg","year":"1992","unstructured":"Hochberg\u00a0MC, Chang\u00a0RW, Dwosh\u00a0I, Lindsey\u00a0S, Pincus\u00a0T, Wolfe\u00a0F (1992) The American college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35(5):498\u2013502","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1165_CR23","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/art.24123","volume":"59","author":"D Aletaha","year":"2008","unstructured":"Aletaha\u00a0D, Landewe\u00a0R, Karonitsch\u00a0T, Bathon\u00a0J, Boers\u00a0M, Bombardier\u00a0C et\u00a0al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations. Arthritis Care Res 59(10):1371\u20131377","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1165_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad\u00a0AR, Moore\u00a0RA, Carroll\u00a0D, Jenkinson\u00a0C, Reynolds\u00a0DJM, Gavaghan\u00a0DJ et\u00a0al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"issue":"4","key":"1165_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher\u00a0D, Liberati\u00a0A, Tetzlaff\u00a0J, Altman\u00a0DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264\u2013269","journal-title":"Ann Intern Med"},{"issue":"1","key":"1165_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/2046-4053-3-110","volume":"3","author":"S Brown","year":"2014","unstructured":"Brown\u00a0S, Hutton\u00a0B, Clifford\u00a0T, Coyle\u00a0D, Grima\u00a0D, Wells\u00a0G et al (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses\u2014an overview and application of NetMetaXL. Syst Rev 3(1):110","journal-title":"Syst Rev"},{"issue":"7521","key":"1165_CR27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell\u00a0DM, Ades\u00a0A, Higgins\u00a0J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897","journal-title":"BMJ"},{"issue":"2","key":"1165_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti\u00a0G, Ades\u00a0A, Ioannidis\u00a0JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J\u00a0Clin Epidemiol 64(2):163\u2013171","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"1165_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias\u00a0S, Welton\u00a0NJ, Sutton\u00a0AJ, Caldwell\u00a0DM, Lu\u00a0G, Ades\u00a0A (2013) Evidence synthesis for decision making 4 inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33(5):641\u2013656","journal-title":"Med Decis Making"},{"issue":"2","key":"1165_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"J Higgins","year":"2012","unstructured":"Higgins\u00a0J, Jackson\u00a0D, Barrett\u00a0J, Lu\u00a0G, Ades\u00a0A, White\u00a0I (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3(2):98\u2013110","journal-title":"Res Synth Methods"},{"issue":"4","key":"1165_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G Valkenhoef","year":"2012","unstructured":"Valkenhoef\u00a0G, Lu\u00a0G, Brock\u00a0B, Hillege\u00a0H, Ades\u00a0A, Welton\u00a0NJ (2012) Automating network meta-analysis. Res Syn Meth 3(4):285\u2013299","journal-title":"Res Syn Meth"},{"issue":"2","key":"1165_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3904\/kjim.2016.195","volume":"33","author":"YH Lee","year":"2018","unstructured":"Lee\u00a0YH (2018) An overview of meta-analysis for clinicians. Korean J Intern Med 33(2):277","journal-title":"Korean J Intern Med"},{"issue":"10","key":"1165_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1759720X17720366","volume":"9","author":"S Ajeganova","year":"2017","unstructured":"Ajeganova\u00a0S, Huizinga\u00a0T (2017) Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis 9(10):249\u2013262","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"1165_CR34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/pds.4126","volume":"26","author":"JR Curtis","year":"2017","unstructured":"Curtis\u00a0JR, Chen\u00a0L, Greenberg\u00a0JD, Harrold\u00a0L, Kilgore\u00a0ML, Kremer\u00a0JM et\u00a0al (2017) The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. Pharmacoepidemiol Drug Saf 26(3):310\u2013319","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1165_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41584-020-00543-5","volume":"17","author":"G Schett","year":"2021","unstructured":"Schett\u00a0G, Tanaka\u00a0Y, Isaacs\u00a0JD (2021) Why remission is not enough: underlying disease mechanisms in RA that prevent cure. Nat Rev Rheumatol 17(3):135\u2013144","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"1165_CR36","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00296-014-2994-2","volume":"34","author":"F Catal\u00e1-L\u00f3pez","year":"2014","unstructured":"Catal\u00e1-L\u00f3pez\u00a0F, Tob\u00edas\u00a0A, Cameron\u00a0C, Moher\u00a0D, Hutton\u00a0B (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int 34(11):1489\u20131496","journal-title":"Rheumatol Int"},{"issue":"12","key":"1165_CR37","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s10067-014-2645-8","volume":"33","author":"GG Song","year":"2014","unstructured":"Song\u00a0GG, Bae\u00a0S\u2011C, Lee\u00a0YH (2014) Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a\u00a0meta-analysis. Clin Rheumatol 33(12):1715\u20131724","journal-title":"Clin Rheumatol"},{"issue":"11","key":"1165_CR38","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00296-010-1526-y","volume":"31","author":"YH Lee","year":"2011","unstructured":"Lee\u00a0YH, Bae\u00a0SC, Song\u00a0GG (2011) The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a\u00a0systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 31(11):1493\u20131499","journal-title":"Rheumatol Int"},{"issue":"1","key":"1165_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11033-011-0712-7","volume":"39","author":"YH Lee","year":"2012","unstructured":"Lee\u00a0YH, Bae\u00a0SC, Choi\u00a0SJ, Ji\u00a0JD, Song\u00a0GG (2012) Associations between interleukin-10 polymorphisms and susceptibility to rheumatoid arthritis: a\u00a0meta-analysis. Mol Biol Rep 39(1):81\u201387","journal-title":"Mol Biol Rep"},{"issue":"3","key":"1165_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4078\/jrd.2020.27.3.152","volume":"27","author":"YH Lee","year":"2020","unstructured":"Lee\u00a0YH, Song\u00a0GG (2020) Circulating interleukin-37 levels in rheumatoid arthritis and systemic lupus erythematosus and their correlations with disease activity: a meta-analysis. J\u00a0Rheum Dis 27(3):152\u2013158","journal-title":"J Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01165-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01165-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01165-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T12:04:30Z","timestamp":1708689870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01165-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":40,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01165-w","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"10 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.H.\u00a0Lee and G.G.\u00a0Song declare that they have no financial or non-financial conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}